Trial Profile
LowEr Administered Dose With highEr Relaxivity: Gadovist vs Dotarem (LEADER 75)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Oct 2021
Price :
$35
*
At a glance
- Drugs Gadobutrol (Primary) ; Gadoterate-meglumine
- Indications CNS cancer
- Focus Diagnostic use
- Acronyms LEADER75
- Sponsors Bayer
- 01 Oct 2021 According to a Bayer media release, Dr. Benjamin P. Liu is the coordinating investigator for this trial.
- 01 Oct 2021 According to a Bayer media release, results from this trial will be published in the print version of the journal in November 2021.
- 01 Oct 2021 According to a Bayer media release, results from this trial were featured online by the American Journal of Roentgenology (AJR) recently.